These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18607012)

  • 21. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
    Ong T; Ramsey BW
    Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystic fibrosis gene therapy: the first trial.
    Arch Dis Child; 2015 Sep; 100(9):844. PubMed ID: 26205882
    [No Abstract]   [Full Text] [Related]  

  • 23. Challenges facing microRNA therapeutics for cystic fibrosis lung disease.
    De Santi C; Greene CM
    Epigenomics; 2020 Feb; 12(3):179-181. PubMed ID: 32011168
    [No Abstract]   [Full Text] [Related]  

  • 24. Prospects for gene therapy in cystic fibrosis.
    Jaffé A; Bush A; Geddes DM; Alton EW
    Arch Dis Child; 1999 Mar; 80(3):286-9. PubMed ID: 10325715
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis.
    Crystal RG; Mastrangeli A; Sanders A; Cooke J; King T; Gilbert F; Henschke C; Pascal W; Herena J; Harvey BG
    Hum Gene Ther; 1995 May; 6(5):667-703. PubMed ID: 7578402
    [No Abstract]   [Full Text] [Related]  

  • 26. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.
    Clunes MT; Boucher RC
    Curr Opin Pharmacol; 2008 Jun; 8(3):292-9. PubMed ID: 18468487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In utero efficacy of cystic fibrosis gene therapy: difficult studies, positive or negative.
    Flotte TR
    Mol Ther; 2008 May; 16(5):806-7. PubMed ID: 18432269
    [No Abstract]   [Full Text] [Related]  

  • 28. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee T; Southern KW
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005599. PubMed ID: 17443603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breathing Easier: Molecular Therapeutics for Cystic Fibrosis.
    Limberis MP
    Hum Gene Ther; 2020 Sep; 31(17-18):905-906. PubMed ID: 32945723
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic options for hydrating airway mucus in cystic fibrosis.
    Tildy BE; Rogers DF
    Pharmacology; 2015; 95(3-4):117-32. PubMed ID: 25823699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.
    Egan ME
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic fibrosis: bench to bedside 2003.
    Rubin BK
    Can Respir J; 2003 Apr; 10(3):161-4. PubMed ID: 12712228
    [No Abstract]   [Full Text] [Related]  

  • 33. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee TW; Southern KW
    Cochrane Database Syst Rev; 2013 Nov; (11):CD005599. PubMed ID: 24282073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 35. Current status of CF gene therapy.
    Boucher RC
    Trends Genet; 1996 Mar; 12(3):81-4. PubMed ID: 8868343
    [No Abstract]   [Full Text] [Related]  

  • 36. delta F508 in cystic fibrosis: willing but not able.
    Southern KW
    Arch Dis Child; 1997 Mar; 76(3):278-82. PubMed ID: 9135274
    [No Abstract]   [Full Text] [Related]  

  • 37. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
    Tarran R; Donaldson S; Boucher RC
    Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].
    Becq F
    Arch Pediatr; 2003 Sep; 10 Suppl 2():325s-332s. PubMed ID: 14671929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superior effect of hypertonic saline over mannitol to attenuate cerebral edema in a rabbit bacterial meningitis model.
    Liu S; Li L; Luo Z; Wang M; She H; Yu X; Deng X; Huang F; Shang L; Jian C; Ji G; Yue S
    Crit Care Med; 2011 Jun; 39(6):1467-73. PubMed ID: 21336112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laying the Foundation for Cystic Fibrosis Therapy: An Interview with Michael Boyle.
    Davies K
    Hum Gene Ther; 2020 Sep; 31(17-18):917-920. PubMed ID: 32924627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.